IP Library Granted Patent US 11,464,809
Granted Patent B2
US 11,464,809 · App. 16/840,554 · Granted Oct 11, 2022

Umbilical tissue compositions and methods of use

Inventors: Alla Danilkovitch (Columbia, MD); Yi Duan-Arnold (Ellicott City, MD); Matthew Moorman (Chestertown, MD); Anne Lerch (Annapolis, MD); Jin-Qiang Kuang (Gleneig, MD)
Assignee: OSIRIS THERAPEUTICS, INC.
A61K35/51A01N1/021A61K35/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,464,809
App. No.
16/840,554
Granted
Oct 11, 2022
Kind
B2
Abstract

Disclosed are compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are compositions comprising a previously cryopreserved umbilical tissue, wherein after cryopreservation and subsequent thawing the umbilical tissue comprises: a) viable cells native to the umbilical tissue; b) tissue integrity of native umbilical tissue; c) one or more growth factors that are native to the umbilical tissue; and d) depleted amounts of one or more types of functional immunogenic cells. Disclosed are methods of producing compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are methods of treating damaged tissue comprising administering to the site of the damaged tissue compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels.

Claims (16)

1. A method of making an umbilical tissue composition, the method comprising:

(a) isolating umbilical tissue from a subject; and

(b) forming one or more engineered channels through at least a portion of the umbilical tissue.

2. The method of claim 1 , further comprising removing blood vessels from the umbilical tissue.

3. The method of claim 2 , wherein said removing causes the umbilical tissue to be devoid of the two arteries and one vein originally present in the umbilical tissue.

4. The method of claim 1 , further comprising removing, depleting, and/or killing immunogenic cells in the umbilical tissue.

5. The method of claim 4 , wherein said removing, depleting, and/or killing causes the umbilical tissue to be devoid of viable immunogenic cells.

6. The method of claim 1 , further comprising cryopreserving the umbilical tissue.

7. The method of claim 6 , wherein the cryopreserved umbilical tissue comprises viable cells native to the umbilical tissue, wherein the viable cells comprise mesenchymal stem cells, fibroblasts, epithelial cells, or a combination thereof.

8. The method of claim 6 , wherein the umbilical tissue comprises one or more growth factors native to the umbilical tissue and/or one or more cytokines native to the umbilical tissue.

9. The method of claim 1 , wherein the umbilical tissue comprises a Wharton's jelly layer side and an amniotic epithelial layer side, wherein the one or more engineered channels are formed on the Wharton's jelly layer side and do not extend through the amnion side.

10. The method of claim 1 , wherein the one or more engineered channels are formed through the entire umbilical tissue.

11. The method of claim 1 , further comprising treating the umbilical tissue with at least one antibiotic.

12. The method of claim 1 , further comprising removing substantially all the umbilical cord blood from the umbilical tissue.

13. The method of claim 1 , wherein forming the one or more engineered channels comprises removal of umbilical cord tissue by mechanical means or by laser.

14. The method of claim 1 , wherein forming the one or more engineered channels comprises displacement of umbilical cord tissue.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2020
From: DANILKOVITCH, ALLA; DUAN-ARNOLD, YI; MOORMAN, MATTHEW; LERCH, ANNE; KUANG, JIN-QIANG
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 052316/0723 →
Continuity (3)
Continuation 15274100 · Sep 23, 2016
Provisional Application 62222446 · Sep 23, 2015
Related Publication 20200390824A1 · Dec 17, 2020